(Updated - August 24, 2021 5:56 AM EDT)

Cowen analyst Marc Frahm downgraded Theravance Biopharma (NASDAQ: TBPH) from Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Theravance Biopharma (TBPH) PT Lowered to $18 at Needham & CompanyAugust 24, 2021 6:24 AM Theravance Biopharma (TBPH) PT Lowered to $14 at BofA SecuritiesAugust 24, 2021 5:21 AM After-Hours Stock Movers 08/23: (CARA) (PANW) (BXC) Higher; (TBPH) (MARK) Lower (more...)August 23, 2021 5:40 PM Theravance Biopharma (TBPH) falls 21% as trading resumes after a trial missed the primary endpointAugust 23, 2021 4:37 PM Form 8-K Theravance Biopharma, For: Aug 23August 23, 2021 4:11 PM Theravance Biopharma (TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpointAugust 23, 2021 4:10 PM Theravance Biopharma (TBPH) Phase 2b Dose-Finding Induction Study of Izencitinib Did Not Meet Primary EndpointAugust 23, 2021 4:07 PM Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative ColitisAugust 23, 2021 4:05 PM Theravance Biopharma (TBPH) halted, news pendingAugust 23, 2021 4:02 PM